793 related articles for article (PubMed ID: 22443427)
21. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
Berg DD; Bonaca MP; Braunwald E; Corbalan R; Goto S; Kiss RG; Murphy SA; Scirica BM; Spinar J; Morrow DA
Am J Cardiol; 2016 Apr; 117(7):1055-8. PubMed ID: 26876014
[TBL] [Abstract][Full Text] [Related]
22. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
Whellan DJ; Tricoci P; Chen E; Huang Z; Leibowitz D; Vranckx P; Marhefka GD; Held C; Nicolau JC; Storey RF; Ruzyllo W; Huber K; Sinnaeve P; Weiss AT; Dery JP; Moliterno DJ; Van de Werf F; Aylward PE; White HD; Armstrong PW; Wallentin L; Strony J; Harrington RA; Mahaffey KW
J Am Coll Cardiol; 2014 Mar; 63(11):1048-57. PubMed ID: 24211500
[TBL] [Abstract][Full Text] [Related]
23. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
Bhandari B; Mehta B
Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
[TBL] [Abstract][Full Text] [Related]
24. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
Leonardi S; Tricoci P; White HD; Armstrong PW; Huang Z; Wallentin L; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Providencia L; Nordrehaug JE; Held C; Strony J; Rorick TL; Harrington RA; Mahaffey KW
Eur Heart J; 2013 Jun; 34(23):1723-31. PubMed ID: 23530022
[TBL] [Abstract][Full Text] [Related]
25. Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.
Ungar L; Rodriguez F; Mahaffey KW
Coron Artery Dis; 2016 Nov; 27(7):604-15. PubMed ID: 27398626
[TBL] [Abstract][Full Text] [Related]
26. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
Duerschmied D; Bode C
Hamostaseologie; 2012; 32(3):221-7. PubMed ID: 22777302
[TBL] [Abstract][Full Text] [Related]
27. Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial.
Kosova EC; Bonaca MP; Dellborg M; He P; Morais J; Oude Ophuis T; Scirica BM; Tendera M; Theroux P; Braunwald E; Morrow DA
Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):164-172. PubMed ID: 27075924
[TBL] [Abstract][Full Text] [Related]
28. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Tricoci P; Lokhnygina Y; Huang Z; Van de Werf F; Cornel JH; Chen E; Wallentin L; Held C; Aylward PE; Moliterno DJ; Jennings LK; White HD; Armstrong PW; Harrington RA; Strony J; Mahaffey KW
Am Heart J; 2014 Dec; 168(6):869-77.e1. PubMed ID: 25458650
[TBL] [Abstract][Full Text] [Related]
29. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.
Held C; Tricoci P; Huang Z; Van de Werf F; White HD; Armstrong PW; Ambrosio G; Aylward PE; Moliterno DJ; Wallentin L; Chen E; Erkan A; Jiang L; Strony J; Harrington RA; Mahaffey KW
Eur Heart J Acute Cardiovasc Care; 2014 Sep; 3(3):246-56. PubMed ID: 24627331
[TBL] [Abstract][Full Text] [Related]
30. Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.
White HD; Huang Z; Tricoci P; Van de Werf F; Wallentin L; Lokhnygina Y; Moliterno DJ; Aylward PE; Mahaffey KW; Armstrong PW
J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25012288
[TBL] [Abstract][Full Text] [Related]
31. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
; Anand S; Yusuf S; Xie C; Pogue J; Eikelboom J; Budaj A; Sussex B; Liu L; Guzman R; Cina C; Crowell R; Keltai M; Gosselin G
N Engl J Med; 2007 Jul; 357(3):217-27. PubMed ID: 17634457
[TBL] [Abstract][Full Text] [Related]
32. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Armaganijan LV; Alexander KP; Huang Z; Tricoci P; Held C; Van de Werf F; Armstrong PW; Aylward PE; White HD; Moliterno DJ; Wallentin L; Chen E; Harrington RA; Strony J; Mahaffey KW; Lopes RD
Am Heart J; 2016 Aug; 178():176-84. PubMed ID: 27502866
[TBL] [Abstract][Full Text] [Related]
33. Review of vorapaxar for the prevention of atherothrombotic events.
Wang A
Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
[TBL] [Abstract][Full Text] [Related]
34. Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50.
Kidd SK; Bonaca MP; Braunwald E; De Ferrari GM; Lewis BS; Merlini PA; Murphy SA; Scirica BM; White HD; Morrow DA
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27431644
[TBL] [Abstract][Full Text] [Related]
35. Vorapaxar in the secondary prevention of atherothrombosis.
Tantry US; Liu F; Chen G; Gurbel PA
Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
[TBL] [Abstract][Full Text] [Related]
36. Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar.
Farag M; Patel H; Gorog DA
Drug Des Devel Ther; 2015; 9():3801-9. PubMed ID: 26229441
[TBL] [Abstract][Full Text] [Related]
37. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.
Harskamp RE; Clare RM; Ambrosio G; Held C; Lokhnygina Y; Moliterno DJ; White HD; Aylward PE; Armstrong PW; Mahaffey KW; Harrington RA; Van de Werf F; Wallentin L; Strony J; Tricoci P
Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):155-163. PubMed ID: 26895973
[TBL] [Abstract][Full Text] [Related]
38. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
Déry JP; Mahaffey KW; Tricoci P; White HD; Podder M; Westerhout CM; Moliterno DJ; Harrington RA; Chen E; Strony J; Van de Werf F; Ziada KM; Held C; Aylward PE; Armstrong PW; Rao SV
Catheter Cardiovasc Interv; 2016 Aug; 88(2):163-73. PubMed ID: 26698636
[TBL] [Abstract][Full Text] [Related]
39. Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial.
ADVICE study group
Lancet HIV; 2018 Oct; 5(10):e553-e559. PubMed ID: 30257802
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials.
Capodanno D; Bhatt DL; Goto S; O'Donoghue ML; Moliterno DJ; Tamburino C; Angiolillo DJ
J Thromb Haemost; 2012 Oct; 10(10):2006-15. PubMed ID: 22845871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
